Leukocyte Ratios Predict Metastasis, Recurrence, and Mortality in Breast Cancer Patients Receiving Cytotoxic Chemotherapy
Authors:
- Carolina CoradiCCCarolina Coradi
- Aedra Carla Bufalo KawassakiAKAedra Carla Bufalo Kawassaki
- Ana Paula VieiraAVAna Paula Vieira
- Camila Elizandra RossiCRCamila Elizandra Rossi
- Caryna Eurich MazurCMCaryna Eurich Mazur
- Claudiceia Risso PascottoCPClaudiceia Risso Pascotto
- Cleide Viviane BuzanelloCBCleide Viviane Buzanello
- Dalila Moter BenvegnúDBDalila Moter Benvegnú
- Franciele Aní Caovilla FoladorFFFranciele Aní Caovilla Folador
- Geraldo Emílio VicentiniGVGeraldo Emílio Vicentini
- Gisele ArrudaGAGisele Arruda
- Guilherme Welter WendtGuilherme Welter Wendt
Open Access
- 26 November 2025
- journal article
- research article
- Published by MDPI AG in Medical Sciences
- Vol. 13 (4) , 285
Abstract
Background/Objectives: Breast cancer is a leading cause of female mortality worldwide. Immune system dynamics, reflected in hematological ratios derived from leukocytes, have been increasingly recognized for their prognostic value in cancer patients. This study aimed to evaluate the clinical significance of leukocyte-based hematological ratios in breast cancer patients undergoing cytotoxic polychemotherapy, focusing on their association with prognosis, chemoresistance, recurrence, metastasis, and mortality. Methods: A mixed observational study was conducted with 185 breast cancer patients undergoing AC-T chemotherapy. Hematologic ratios, including neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR), were calculated at multiple treatment points (D0–D168) and correlated with clinical outcomes. Statistical analyses included ANOVA and ROC curve evaluations to determine the prognostic accuracy of these markers. Results: Significant alterations in hematological ratios were observed during chemotherapy. An increase in MLR correlated with intermediate risk for death and metastasis, while elevated PLR and platelet-to-neutrophil ratio (PNR) were strongly associated with metastasis, recurrence, and mortality. Decreases in lymphocyte-to-platelet ratio (LPR) were linked to chemoresistance and adverse outcomes. ROC curve analysis identified PLR at D84 (sensitivity: 83.33%) and PNR at D126 (specificity: 87.01%) as robust prognostic markers. Conclusions: Leukocyte-based hematological ratios provide valuable insights into immune dynamics and prognosis in breast cancer patients undergoing chemotherapy. Their integration into routine clinical evaluations could enhance risk stratification and personalized treatment approaches.Keywords
Funding Information
- Brazilian National Council for Scientific and Technological Development (408588/2025-0, 303076/2025-9)
- Secretariat of Science, Technology, and Higher Education of the State of Paraná (220/2024)
- Fundação Araucária (147/2025, 08/2025)
This publication has 55 references indexed in Scilit:
- Harnessing hematological ratios: prognostic insights for breast cancer managementClinical and Translational Oncology, 2024
- Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityCancer Cell, 2022
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Annals of Oncology, 2021
- Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemiaCritical Reviews in Oncology/Hematology, 2020
- Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancerCochrane Database of Systematic Reviews, 2019
- Cyclooxygenase-Dependent Tumor Growth through Evasion of ImmunityCell, 2015
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancerCritical Reviews in Oncology/Hematology, 2013
- Immunity, Inflammation, and CancerCell, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- DIRECT INFLUENCES OF PRO-INFLAMMATORY CYTOKINES (IL-1β, TNF-α, IL-6) ON THE PROLIFERATION AND CELL-SURFACE ANTIGEN EXPRESSION OF CANCER CELLSCytokine, 2000